HRS-9231

Unknown / undisclosed

Phase 1Mechanism not established
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT07275814 · Shanghai Shengdi Pharmaceutical Co., Ltd
2025-11-17 – 2026-06-17 · For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
What this study did
NCT07275723 · Shanghai Shengdi Pharmaceutical Co., Ltd
2025-11-14 – 2026-06-09 · For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)
What this study did
Phase 2 (1)
Other / comorbidity
NCT06731829 · Jiangsu HengRui Medicine Co., Ltd.
2024-12 – 2025-04 · For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
What this study did
Phase 1 (3)
Other / comorbidity
NCT06657560 · Shanghai Shengdi Pharmaceutical Co., Ltd
2024-10-14 – 2025-07-03 · Contrast-Enhanced Magnetic Resonance Imaging Detection
What this study did
NCT06519981 · Atridia Pty Ltd.
2024-08-21 – 2024-11-27 · MRI
What this study did
NCT07123376 · Shanghai Shengdi Pharmaceutical Co., Ltd
2024-06-05 – 2024-10-06 · Healthy Volunteers
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.